Pharmacogenomics of coumarin anticoagulants : Are we underestimating the role of CYP2C9?SCHALEKAMP, Tom; MAITLAND -VAN DER ZEE, Anke-Hilse; DE BOER, Anthonius et al.Thrombosis and haemostasis. 2008, Vol 100, Num 2, pp 175-176, issn 0340-6245, 2 p.Article

Differential Genotype Dependent Inhibition of CYP2C9 in HumansKUMAR, Vikas; BRUNDAGE, Richard C; OETTING, William S et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1242-1248, issn 0090-9556, 7 p.Article

Re-engineering of CYP2C9 to Probe Acid-Base Substrate SelectivityGUOYING TAI; DICKMANN, Leslie J; MATOVIC, Nicholas et al.Drug metabolism and disposition. 2008, Vol 36, Num 10, pp 1992-1997, issn 0090-9556, 6 p.Article

Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor PanelsNATH, Abhinav; ATKINS, William.Drug metabolism and disposition. 2008, Vol 36, Num 11, pp 2151-2155, issn 0090-9556, 5 p.Article

Frequency of cytochrome P450 2C9 mutant alleles in a Korean populationYOON, Young-Ran; SHON, Ji-Hong; KIM, Moon-Kyung et al.British journal of clinical pharmacology. 2001, Vol 51, Num 3, pp 277-280, issn 0306-5251Article

Mechanism of CYP2C9 Inhibition by Flavones and FlavonolsDAYONG SI; YING WANG; ZHOU, Yi-Han et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 629-634, issn 0090-9556, 6 p.Article

CYP2C9-CYP3A4 Protein-Protein Interactions: Role of the Hydrophobic N TerminusSUBRAMANIAN, Murali; TAM, Harrison; ZHENG, Helen et al.Drug metabolism and disposition. 2010, Vol 38, Num 6, pp 1003-1009, issn 0090-9556, 7 p.Article

Electrocatalytic Drug Metabolism by CYP2C9 Bonded to A Self-Assembled Monolayer-Modified ElectrodeMINGLI YANG; KABULSKI, Jarod L; WOLLENBERG, Lance et al.Drug metabolism and disposition. 2009, Vol 37, Num 4, pp 892-899, issn 0090-9556, 8 p.Article

Short communication: Characterization of the novel defective CYP2C9*24 alleleHERMAN, Darja; DOLZAN, Vita; INGELMAN-SUNDBERG, Magnus et al.Drug metabolism and disposition. 2007, Vol 35, Num 6, pp 831-834, issn 0090-9556, 4 p.Article

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese populationKIMURA, M; IEIRI, I; MAMIYA, K et al.Therapeutic drug monitoring. 1998, Vol 20, Num 3, pp 243-247, issn 0163-4356Article

CYP2C9 protein interactions with cytochrome b₅ : Effects on the coupling of catalysisLOCUSON, Charles W; WIENKERS, Larry C; JONES, Jeffrey P et al.Drug metabolism and disposition. 2007, Vol 35, Num 7, pp 1174-1181, issn 0090-9556, 8 p.Article

Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissuesDELOZIER, Tracy C; KISSLING, Grace E; COULTER, Sherry J et al.Drug metabolism and disposition. 2007, Vol 35, Num 4, pp 682-688, issn 0090-9556, 7 p.Article

CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and CatalysisSUBRAMANIAN, Murali; LOW, Michael; LOCUSON, Charles W et al.Drug metabolism and disposition. 2009, Vol 37, Num 8, pp 1682-1689, issn 0090-9556, 8 p.Article

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in HealthyVolunteersVORMFELDE, S. V; BROCKMÖLLER, J; BAUER, S et al.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 1, pp 54-61, issn 0009-9236, 8 p.Article

Simultaneous Determination of Warfarin and 7-Hydroxywarfarin Enantiomers by High-Performance Liquid Chromatography With Ultraviolet DetectionMIURA, Masatomo; OKUYAMA, Shin; KATO, Shoutaro et al.Therapeutic drug monitoring. 2011, Vol 33, Num 1, pp 108-114, issn 0163-4356, 7 p.Article

Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9SACHSE-SEEBOTH, C; PFEIL, J; SEHRT, D et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 3, pp 273-276, issn 0009-9236, 4 p.Article

Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profilesKUMAR, Vikas; LOCUSON, Chuck W; SHAM, Yuk Y et al.Drug metabolism and disposition. 2006, Vol 34, Num 10, pp 1688-1696, issn 0090-9556, 9 p.Article

Involvement of hepatocyte nuclear factor 4α in the different expression level between CYP2C9 and CYP2C19 in the human liverKAWASHIMA, Sachiyo; KOBAYASHI, Kaoru; TAKAMA, Kaori et al.Drug metabolism and disposition. 2006, Vol 34, Num 6, pp 1012-1018, issn 0090-9556, 7 p.Article

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levelsKERB, R; AYNACIOGLU, A. S; GÜZELBEY, P et al.Pharmacogenomics journal (Print). 2001, Vol 1, Num 3, pp 204-210, issn 1470-269XArticle

Pharmacokinetics and safety of the sesame lignans, sesamin and episesamin, in healthy subjectsTOMIMORI, Namino; TANAKA, Yasuhiro; KITAGAWA, Yoshinori et al.Biopharmaceutics & drug disposition. 2013, Vol 34, Num 8, pp 462-473, issn 0142-2782, 12 p.Article

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (^*8) PolymorphismLIU, Y; JEONG, H; TAKAHASHI, H et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 4, pp 660-665, issn 0009-9236, 6 p.Article

Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interactionFANG, Zhong-Ze; ZHANG, Yan-Yan; GE, Guang-Bo et al.British journal of clinical pharmacology. 2010, Vol 69, Num 2, pp 193-199, issn 0306-5251, 7 p.Article

CYP2C9 polymorphisms in human tumorsKNÜPFER, Heike; STANITZ, Dirk; PREISS, Rainer et al.Anticancer research. 2006, Vol 26, Num 1A, pp 299-305, issn 0250-7005, 7 p.Article

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9XIA WEN; WANG, Jun-Sheng; BACKMAN, Janne T et al.Drug metabolism and disposition. 2001, Vol 29, Num 11, pp 1359-1361, issn 0090-9556Article

In Vitro Assessment of 36 CYP2C9 Allelic Isoforms Found in the Chinese Population on the Metabolism of GlimepirideDAI, Da-Peng; WANG, Shuang-Hu; GENG, Pei-Wu et al.Basic & clinical pharmacology & toxicology (Print). 2014, Vol 114, Num 4, pp 305-310, issn 1742-7835, 6 p.Article